Search results :

Zoledronic acid

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: M05BA08

Side effects

Options: Show MedDRA Preferred Terms,   display all 40 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Neoplasm malignant aggravated 17% - 20% 20% x x x x x x x x x
Anaemia postmarketing — 4.4% - 22% 3.6% - 5.2% x x x x x
Urinary tract infection 12% - 15% x x x x x x x x x x x
Insomnia 10% - 13% x x x x x x x x x x x
Pain in extremity 3.9% - 16% 4.8% - 9.9% x x x x x x x x x x x x x x x
Confusional state rare, 11% - 13% x x x x x x x x x x x x x
Cough uncommon, 10% - 12% x x x x x x x x x x x x x x
Hypokalaemia uncommon, 10% - 16% x x x x x x x x x x x x x
Agitation 8% - 11% x x x x x x x x x x
Headache postmarketing — 3.9% - 20.4% 2.5% - 11.4% x x x x x x x x x x x x x x x x x x x x
Anxiety uncommon, 8% - 12% x x x x x x x x x x x x x
Osteoarthritis 5.7% - 9.1% 4.5% - 9.7% x x
Candida infection 4% - 12% x x x x x x x x x x
Hypophosphataemia common — 1% - 51% 0.2% - 3% x x x x x x x x x x x x x
Hypertension uncommon — 5.1% - 12.7% 5.4% - 12.4% x x x x x x
Influenza 5% - 7% x x x x x x x
Constipation uncommon — 5% - 23% 6.9% x x x x x x x x x x x x x x x x x x x
Diarrhoea postmarketing — 5.2% - 17% 4.7% - 7.9% x x x x x x x x x x x x x x x x x x x x
Nausea postmarketing — 4.5% - 28% 4.5% - 7.9% x x x x x x x x x x x x x x x x x x x x
Non-cardiac chest pain 3.5% - 7.7% 3% x x
Back pain 1.7% - 18.2% 11.9% x x x x x x x x x x x x x x x x
Arthralgia postmarketing — 3% - 27.3% 18.3% - 20.4% x x x x x x x x x x x x x x x x x x x x
Dyspnoea uncommon — 1% - 20% x x x x x x x x x x x x x x x x x x x x
Oesophagitis common x
Flushing common x x x x x
Nasopharyngitis common x x
Pain uncommon — 1.5% - 24.2% 0.5% - 3.5% x x x x x x x x x x
Tachycardia common
Thirst common x
Blood urea increased common x x
Bone pain postmarketing — 3.2% - 12% 1% - 2.3% x x x x x x x x x x x x x x x x x x x x
Rigors common, 1% - 8% x x x x x x x x x x x x x x x x x x
Stiffness common
Musculoskeletal chest pain common x x
Renal impairment postmarketing, common x x
Neck pain 1.4% - 6.6% 1.1% - 5% x x x
Breast cancer 4.3% x x x x x x x x x x x
Joint stiffness common, 1.1% - 3.5% 2% x x x
Infection postmarketing, 4% - 12% x x x x x x x x x x x x x x x x x x x
Dizziness uncommon, 2% - 9% 3.5% - 6.7% x x x x x x x x x x x x x x x x x x x
Dyspepsia uncommon — 1.7% - 7.1% 1.6% - 5% x x x x x x x x x x x x x x x x x x
Shoulder pain 0% - 6.9% 0% - 5.6% x x x
Lethargy common, 1% - 5% x x x x x x x
Muscle spasms 1.5% - 5.6% 1.7% - 5% x x x
Neoplasm 3.2% x x
Prostate cancer 3.1% x x
Oedema peripheral uncommon — 1% - 5.6% 3.5% - 5.3% x x x x x x x x x x
C-reactive protein increased 1.4% - 4.6% x x
Pain in jaw 2% - 3.9% 2.5% x
Hyperhidrosis common, 2% - 2.6% x x x
Atrial fibrillation uncommon, 2% - 3.3% 1.9% - 2.6% x
Fatigue postmarketing — 2.1% - 17.6% 1.2% - 4% x x x x x x x x x x x x x x x x x x x
Creatinine renal clearance decreased 2% - 2.1% 1.7% - 2.4% x
Myalgia postmarketing — 4% - 22.7% 2.7% - 6.9% x x x x x x x x x x x x x x x x x x x x
Abdominal pain uncommon — 2% - 14% 7.9% x x x x x x x x x x x x x x x x x x x
Anorexia common, 0.6% - 14% 0% - 1.1% x x x x x x x x x x x x x x x x x x x x
Rash uncommon, 2% - 3% 2.5% x x x x x x x x x x x x x x x x x x x
Body temperature increased postmarketing — 0.3% - 38% 0.1% - 4.6% x x x x x x x x x x x x x x x x x x x x
Hypotension uncommon, 2% - 11% x x x x x x x x x x x x x
Vomiting postmarketing — 2% - 17% 3.2% - 4.5% x x x x x x x x x x x x x x x x x x x x
Vertigo 1.3% - 4.3% 1% - 4% x x x x x x x x x x x x
Abdominal discomfort 1.1% - 2% 0.5% x
Abdominal distension 0.6% - 2% 0% x x x x x
Abdominal pain upper 0.9% - 4.6% 1.5% - 3.1% x x x x x x x
Musculoskeletal stiffness 0% - 4.6% x x x x x x
Blood creatinine increased 0.7% - 2% x x x
Flank pain 0.6% - 2% 0% x
Chest pain uncommon, 1.3% - 2.4% 1.1% - 1.8% x x x x x x x x x x x x x x
Palpitations 0% - 2.6% x x
Hypermagnesaemia 1% - 2% 0.5% - 2% x x x x x x x x
Asthenia postmarketing — 1% - 6.1% 1% - 3% x x x x x x x x x x x x x x x x x x x x
Eye pain 0% - 2% x x
Hypoaesthesia uncommon, 2.2% - 5.6% 2% x x x x x x x x x x x x x
Leukopenia uncommon x x x
Paraesthesia uncommon — 0% - 2% x x x x x x x x x x x x x x x x x x
Pruritus uncommon x x x x x x x x x x x x x x x x
Sleep disturbance uncommon x x
Stomatitis uncommon x x x x x x x x x x x
Swelling uncommon x x x x x x x x x x x x x x x
Syncope uncommon x x x
Thrombocytopenia uncommon x x x x x x x x x x x x x
Injection site reaction uncommon x x x x x x x x x x x x
Rash macular uncommon x x x
Induration uncommon x x x
Redness uncommon x x x x x x x x x x x x x x
Somnolence uncommon x x x x x x x x x x x x x x
Hypocalcaemia very rare — 1% - 3% 0.2% - 1% x x x x x x x x x x x x x x x x x x x x
Hypomagnesaemia uncommon, 1% - 9% 1% - 2% x x x x x x x x x x x x x
Acute phase reaction postmarketing — 0% - 3.9% x x x x x x x x x x x x x x x x
Anaphylactic shock postmarketing, uncommon x x x x x x x x x x x x x x x x
Angioedema postmarketing, rare x x x x x x x x x x x x x x x x
Arthritis postmarketing — 2.2% - 4% 1.5% x x x x x x x
Coagulopathy postmarketing x x x x
Bronchospasm postmarketing x x x x x x x
Neoplasm malignant postmarketing, 14% - 21% x x x x x x x x
Conjunctivitis postmarketing, common x x x x x x x x x x x x x x x x x x x
Dehydration postmarketing, 0.6% - 2.5% 0.6% - 2.3% x x x x x x x x x x x x x x x x x
Dysgeusia postmarketing, uncommon x x x x x x x x x x
Oedema postmarketing x x x x
Episcleritis very rare, postmarketing x x x x x x x x x x x x x x x x x
Femur fracture postmarketing x x x x x x x x x
Haematuria postmarketing, uncommon x x x x x x x x x x
Hyperaesthesia postmarketing, uncommon x x x x x x x x x x
Hyperkalaemia postmarketing, rare x x x x x x x x x x
Hypernatraemia postmarketing, rare x x x x x x x x x x
Hypersensitivity postmarketing, uncommon x x x x x x x x x x x x x x x x
Inflammation postmarketing, uncommon x x x x x x x x x x x x x x x
Iridocyclitis postmarketing x x x x
Iritis postmarketing x x x x x x x x x x x x x x
Renal failure acute postmarketing, uncommon x x x x x x x x x x
Oral disorder postmarketing x x x
Plasma cell myeloma postmarketing, 3.2% x x x x x x x x x
Cramp muscle postmarketing, uncommon x x x x x x x x x x
Musculoskeletal pain postmarketing — 0.4% - 12.4% 0.3% - 7.9% x x x x x x x x x x
Osteonecrosis postmarketing x x x x x x x x x x x
Pancytopenia rare x x x x x x x x x x x x x
Proteinuria postmarketing, uncommon x x x x x x x x x x x x
Scleritis postmarketing, uncommon x x x x x x x x x x x x x x x
Shock postmarketing, uncommon x x x x x x x x x x x x x x x x
Tremor postmarketing, uncommon x x x x x x x x x x x
Urticaria postmarketing, uncommon x x x x x x x x x
Uveitis very rare — uncommon x x x x x x x x x x x x x x x x x
Weight increased postmarketing, uncommon x x x x x x x x x x
Dry mouth postmarketing, uncommon x x x x x x x x x x x
Bronchoconstriction postmarketing, uncommon x x x x x x x x x x x x x x x x
Chills postmarketing, 1.5% - 18.2% 0.5% - 3% x x x x x x x x x x x x x
Joint swelling postmarketing — 0.6% - 3% 0% x x x x x x x
Interstitial lung disease postmarketing, rare x x x x x x x x x
Fatal outcomes postmarketing x x x
Malaise postmarketing — 0.7% - 7.2% 0.5% - 1% x x x x x x x x x x x x
Vision blurred postmarketing, uncommon x x x x x x x x x x
Exacerbation of asthma postmarketing x x x x
Influenza-like symptoms postmarketing, 6.7% - 8% x x x x x x
Orbital oedema postmarketing x x x x x x
Bradycardia rare x x x
Influenza like illness postmarketing, 0.8% - 11% 0.4% - 2.7% x x x x x x x x x x x x x x x x
Sweating increased postmarketing, uncommon x x x x x x x x x
Osteonecrosis of jaw postmarketing, uncommon x x x x x x x x x x x x x x x x x
Advanced breast cancer postmarketing x x x x x x x
Arrhythmia very rare x x
Numbness very rare x x
Convulsion very rare x x
Tetany very rare x x
Agranulocytosis x x x x x x x x x x
Alopecia x x x x x x x x x
Atrial flutter x
Mental disorder x x x x
Bone disorder x x x x x x x
Connective tissue disorder x x x x x
Dysphagia x x x x x x x x x x
Depression x x x x x x x x
Dermatitis x x x x x x x x x
Endophthalmitis x x x
Eye disorder x x x x x
Gastritis x
Gastrooesophageal reflux disease x
Gastrointestinal disorder x x x x x x x x x x
Cardiac disorder x x x x x x
Hypogonadism x
Immune system disorder x x x x
Insomnia NEC
Renal failure chronic x
Mediastinal disorder x x x x x x x x x
Musculoskeletal disorder
Necrosis ischaemic x
Metastasis x x x
Nervous system disorder x x x x x x x x x x
Neutropenia x x x x x x x x
Night sweats
Osteomyelitis x x x
Osteopenia x
Pleural effusion x x x
Renal failure x x x x x x x x x x x x x
Toothache x
Erythema x
Upper respiratory tract infection x x x x x x x x x
Pollakiuria x
Urinary tract disorder x x x x x
Angiopathy x x x x
Weight decreased x x x x x x x x x
Spinal fracture
Cataract x
Electrolyte abnormality x x
Muscular weakness x
Ocular hyperaemia x
Malnutrition x x x x x x x
Unspecified disorder of skin and subcutaneous tissue x x x x x x x x x
Cardiac fibrillation x
Decreased appetite x x x x x x x x x x
Abdominal pain lower x
Leg edema x x x x x x x x x x
Creatinine low x
Edema of lower extremities x x x x x x x x x
Throat sore x x x x x x x x
Azotaemia x
Mucosal inflammation x x x x x x x x x x
Anxiety depression x
Serum creatinine abnormal x x x x x x x x x x
Reaction gastrointestinal x x x x
Nephropathy toxic x x x x x x x x x
Renal cancer x x x x x x x
Infestation NOS x x x x x x x
Blood and lymphatic system disorders x x x x
Ear and labyrinth disorders x x x
Sleep disorder x
Paraesthesia NEC
Anxiety NEC
Local reaction x x x x x x x x x x x x x x x
Infusion related reaction
Infusion site reaction x
Bone mass decreased x
Atypical femur fracture x x
Blood calcium decreased x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

zoledronic acid / Zometa

Side effects:46
Source:FDA

ZOLEDRONIC ACID / RECLAST

Side effects:49
Source:FDA

ZOLEDRONIC ACID ANHYDROUS

Side effects:57
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:60
Source:FDA Structured Product Label

Zoledronic Acid Anhydrous

Side effects:61
Source:FDA Structured Product Label

zoledronic acid / Zometa

Side effects:65
Source:FDA

ZOLEDRONIC ACID / ACLASTA

Side effects:69
Source:Health Canada

ZOLEDRONIC ACID / ZOMETA

Side effects:76
Source:FDA

Zoledronic Acid / Zometa, Powder for infusion

Side effects:98
Source:Medsafe

ZOLEDRONIC ACID / ZOMETA

Side effects:99
Source:FDA

ZOLEDRONIC ACID ANHYDROUS

Side effects:103
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:103
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:104
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:104
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:106
Source:FDA Structured Product Label

zoledronic acid anhydrous

Side effects:106
Source:FDA Structured Product Label

Zoledronic Acid Anhydrous

Side effects:106
Source:FDA Structured Product Label

zoledronic acid / zoledronic acid

Side effects:106
Source:EMA

zoledronic acid / zoledronic acid

Side effects:109
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label